Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Nov 1;33(6):502-509.
doi: 10.1097/MOU.0000000000001118. Epub 2023 Aug 2.

The role of nuclear medicine tracers for prostate cancer surgery: from preoperative to intraoperative setting

Francesco Barletta  1 , Francesco Ceci  2 , Roderick C N van den Bergh  3 , Pawel Rajwa  4   5 , Francesco Montorsi  1 , Alberto Briganti  1 , Giorgio Gandaglia  1 ; EAU-YAU Prostate Cancer Working Party
Affiliations
Review

The role of nuclear medicine tracers for prostate cancer surgery: from preoperative to intraoperative setting

Francesco Barletta et al. Curr Opin Urol. .

Abstract

Purpose of review: There has been a growing interest in the use of novel molecular imaging modalities for the management of prostate cancer (PCa), spanning from diagnostic to therapeutic settings. The aim of this review is to provide a comprehensive overview of recently published studies investigating the use of novel nuclear medicine tracers across different stages of PCa management.

Recent findings: Emerging evidence supports the use of molecular imaging for preoperative staging of PCa, where prostate-specific membrane antigen (PSMA) PET has shown superior accuracy compared to conventional imaging for the detection of nodal and distant metastases, which needs to be translated to new risk stratification. A role for PSMA PET has been proposed for PCa diagnosis, with local activity associated with histology. Surgical guidance, using either visual feedback or gamma-ray detectors to identify tissues with accumulated radio-labeled tracers, may improve the ability to resect locoregional diseases and thus maximize oncological control. PSMA targeted therapy (Lu-PSMA) has been mainly investigated in the castration-resistant setting, but might have a role in earlier settings such as neoadjuvant treatment.

Summary: Novel molecular imaging using PSMA-based tracers could significantly improve PCa management in the diagnosis, staging, and intraoperative guidance settings, potentially leading to personalized and effective treatment decisions.

PubMed Disclaimer

References

    1. Gandaglia G, Leni R, Bray F, et al. Epidemiology and prevention of prostate cancer. Eur Urol Oncol 2021; 4:877–892.
    1. Fletcher SA, von Landenberg N, Cole AP, et al. Contemporary national trends in prostate cancer risk profile at diagnosis. Prostate Cancer Prostatic Dis 2020; 23:81–87.
    1. Heesakkers RAM, Adang EM, Jager GJ, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 2008; 63:387–395.
    1. Maurer T, Eiber M, Schwaiger M, Gschwend JE. Current use of PSMA-PET in prostate cancer management. Nat Rev Urol 2016; 13:226–235.
    1. Perera M, Papa N, Roberts M, et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer — updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review. Eur Urol 2019; 77:403–417.

MeSH terms

Substances